Highlights

  • Pacific Edge's retail offer attracted NZ$46M in applications against a base size of NZ$6M; the company accepted NZ$4.7M in oversubscriptions, raising a total of NZ$10.7M under the retail component and NZ$36.1M in aggregate.
  • Over 93% of total Capital raised came from existing shareholders, signalling a high level of continuity of support ahead of the company's reimbursement inflection with the US Centers for Medicare and Medicaid Services.
  • Cxbladder's commercial momentum includes a draft Local Coverage Determination (LCD) from CMS, a supportive Contractor Advisory Committee meeting in February 2026, growing commercial payer recognition, and early wins in the APAC market.

 

Pacific Edge Limited (ASX:PEB), a New Zealand-headquartered cancer diagnostics company, completed its NZ$36.1M capital raising on 3 June 2026 with the allotment of shares under its retail offer. The company develops and commercialises the Cxbladder suite of non-invasive genomic urine tests, which are used for risk stratification of urothelial cancer in patients presenting with blood in the urine (hematuria) and those under surveillance for recurrent disease.

The fundraising is a pivotal moment for Pacific Edge, which has been navigating a prolonged period of US reimbursement uncertainty following the loss of Medicare coverage via a prior Novitas Local Coverage Determination (LCD) review. The capital raised is intended to fund operations through to a resolution of the reimbursement question — a resolution that appears to be closer following the February 2026 Contractor Advisory Committee (CAC) meeting and a subsequent draft LCD.

The Capital Raise: Mechanics and Outcome

The raising was structured in two components. A NZ$25.4M Placement was completed in mid-May 2026, followed by a NZ$6M retail offer (with the ability to accept oversubscriptions at the board's discretion). The retail offer closed on 28 May 2026 and attracted total applications of NZ$46.0M — approximately 7.7 times the base offer size.

The directors resolved to accept NZ$4.7M of oversubscriptions, resulting in the retail offer raising NZ$10.7M in total. This scaling approach was designed to ensure the vast majority of participating shareholders received at least sufficient allocation to maintain their pre-raise proportional holding. Of the NZ$10.7M, NZ$10.2M is being issued under share purchase plan rules and NZ$0.5M under Pacific Edge's placement capacity. In total, 62,703,746 new shares are being issued at NZ$0.17 per share under the retail offer component.

Shareholder Support: 93% From Existing Holders

One of the more notable aspects of the capital raise outcome is that over 93% of the NZ$36.1M raised came from existing shareholders. Chairman Simon Flood specifically highlighted this figure in the company's closing announcement. In the context of a company that has faced prolonged Medicare reimbursement uncertainty, the retention of such a high proportion of existing shareholder capital indicates that the investor base retains conviction in the Cxbladder thesis and is willing to fund the company through to the expected reimbursement resolution.

Cxbladder: The Commercial and Regulatory Backdrop

The strategic importance of this capital raise is best understood in the context of the Cxbladder commercial pathway. The test is a genomic urine-based diagnostic designed to reduce unnecessary invasive cystoscopy procedures in patients presenting with hematuria. The clinical evidence base spans over 20 years of research and more than 25 peer-reviewed publications, and Cxbladder Triage is included in the American Urological Association's Microhematuria Guideline — a meaningful clinical endorsement.

In the US, Cxbladder has been used by over 5,000 urologists who have collectively ordered more than 130,000 tests. The product is accessible in the US, Australasia, Israel, and selected markets across Asia and South America. The company's path to profitability, however, is critically dependent on achieving secure, broad-based US Medicare reimbursement — the dominant payer for the population segment (older adults with hematuria) most likely to benefit from the test.

The Draft LCD and Pathway to Reimbursement

The pivotal near-term catalyst for Pacific Edge is the outcome of the CMS Medicare LCD process. The February 2026 Novitas-convened CAC meeting — described by the chairman as demonstrating the quality of Cxbladder's clinical evidence and strength of support from the clinical community — was followed by a draft LCD. The issuance of a draft LCD is a formal step in the CMS coverage process that precedes a final coverage determination, and its existence signals meaningful progress toward restored reimbursement access.

Growing recognition from commercial payers and early wins in the APAC market provide parallel Revenue contribution while the US Medicare pathway progresses. In New Zealand, Cxbladder is accessible to approximately 70% of the population via public healthcare, and all New Zealand residents can purchase the test online — providing a stable domestic revenue base.

Conclusion

Pacific Edge's completion of a NZ$36.1M capital raise, with its retail offer oversubscribed by a Factor of approximately 7.7x and 93% of capital sourced from existing shareholders, is an outcome that reflects genuine investor conviction at a critical juncture. The company is now funded through to what it anticipates will be a meaningful inflection in the Cxbladder US reimbursement story. The draft LCD, growing commercial payer recognition, and expanding APAC footprint provide multiple avenues for news flow in the near term. The quality of the capital raise outcome sets a constructive tone for the next phase of Pacific Edge's commercial development.